SONATA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SONATA (SONATA).
Zaleplon is a non-benzodiazepine hypnotic that selectively binds to the benzodiazepine type 1 (BZ1) receptor subtype on the gamma-aminobutyric acid (GABA) A receptor complex, potentiating GABA-mediated chloride ion influx and neuronal inhibition.
| Metabolism | Primarily metabolized by aldehyde oxidase to inactive metabolites; also undergoes metabolism by CYP3A4 to a lesser extent. |
| Excretion | Approximately 83% of administered radioactivity is excreted in urine (with less than 1% as unchanged drug) and 17% in feces. |
| Half-life | Terminal elimination half-life is approximately 1 hour (range 0.7–1.7 h) in healthy adults; elderly patients and those with hepatic impairment may have prolonged half-life (up to 2–3 h). |
| Protein binding | Approximately 50–60% bound to plasma proteins (albumin). |
| Volume of Distribution | Mean volume of distribution is approximately 1.0 L/kg (range 0.6–1.5 L/kg), indicating moderate tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 30% due to extensive first-pass metabolism; sublingual and oral routes have comparable bioavailability. |
| Onset of Action | Oral administration: onset of sleep occurs within 15–30 minutes. |
| Duration of Action | Duration of hypnotic effect is approximately 3–4 hours; early-morning insomnia or next-day sedation are less likely due to short half-life. |
10 mg orally at bedtime; range 5-20 mg; maximum 20 mg per day.
| Dosage form | CAPSULE |
| Renal impairment | No specific adjustment recommended; use with caution in severe renal impairment (CrCl <30 mL/min) due to limited data. |
| Liver impairment | Child-Pugh Class A or B: 5 mg orally at bedtime; Class C: contraindicated. |
| Pediatric use | Not approved for use in children under 18 years; safety and efficacy not established. |
| Geriatric use | Initial dose 5 mg orally at bedtime; maximum 10 mg per day due to increased sensitivity and risk of falls. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SONATA (SONATA).
| Breastfeeding | Excreted in breast milk; M/P ratio not established. Limited human data; infant exposure may cause sedation or feeding difficulties. Caution advised; monitor infant for drowsiness and poor suckling. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Limited data, but animal studies show increased fetal abnormalities (cleft palate, skeletal malformations) at high doses. Second and third trimesters: Risk of neonatal withdrawal or sedation (hypotonia, respiratory depression) if used near term. Avoid unless benefit outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to zaleplon or any component of the formulation"]
| Precautions | ["Complex sleep behaviors including sleep-driving, making phone calls, preparing and eating food, and other activities while not fully awake","CNS depressant effects; risk of additive effects when co-administered with other CNS depressants","Anaphylaxis and angioedema","Abnormal thinking and behavioral changes","Withdrawal effects upon rapid dose reduction or discontinuation","Worsening of depression or suicidal ideation","Respiratory depression risk in patients with compromised respiratory function"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal sedation, respiratory rate, and blood pressure. Fetal monitoring: Non-stress test or biophysical profile if used chronically in third trimester. Assess neonatal adaptation (Apgar scores, respiratory effort) at delivery. |
| Fertility Effects | No significant impact on fertility reported in animal or human studies. Zolpidem does not appear to alter menstrual cycle or spermatogenesis at therapeutic doses. |